These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12864)

  • 41. Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
    Koller-Lucae SK; Suter MJ; Rentsch KM; Schott H; Schwendener RA
    Drug Metab Dispos; 1999 Mar; 27(3):342-50. PubMed ID: 10064564
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL; Rustum YM
    Cancer Res; 1985 May; 45(5):2002-7. PubMed ID: 3986756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antileukemic activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine, a new depot form of 1-beta-D-arabinofuranosylcytosine.
    Khwaja TA; Kigwana LJ; Mian AM
    Cancer Res; 1979 Aug; 39(8):3129-33. PubMed ID: 455296
    [No Abstract]   [Full Text] [Related]  

  • 44. 1-beta-D-arabinofuranosylcytosine-diphosphate-choline is formed by the reversal of cholinephosphotransferase and not via cytidylyltransferase.
    Kucera GL; Capizzi RL
    Cancer Res; 1992 Jul; 52(14):3886-91. PubMed ID: 1377599
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides.
    Sinkule JA; Evans WE
    J Chromatogr; 1983 May; 274():87-93. PubMed ID: 6575975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enzyme catalyzation of the deacylation of N4-acyl derivatives of 1-beta-D-arabinofuranosylcytosine in the mouse liver microsome.
    Tsuruo T; Hori K; Iida H; Tsukagoshi S; Sakurai Y
    Cancer Res; 1982 Jun; 42(6):2250-4. PubMed ID: 7074607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
    White JC; Hines LH
    Cancer Res; 1987 Apr; 47(7):1820-4. PubMed ID: 3028615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preparation and properties of O'-methyl and O'-ethyl derivatives of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil.
    Darzynkiewicz E; Shugar D
    Acta Biochim Pol; 1974; 21(3):305-22. PubMed ID: 4440349
    [No Abstract]   [Full Text] [Related]  

  • 50. Synthesis, transport and pharmacokinetics of 5'-amino acid ester prodrugs of 1-beta-D-arabinofuranosylcytosine.
    Sun Y; Sun J; Shi S; Jing Y; Yin S; Chen Y; Li G; Xu Y; He Z
    Mol Pharm; 2009; 6(1):315-25. PubMed ID: 19115956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancing the efficacy of Ara-C through conjugation with PAMAM dendrimer and linear PEG: a comparative study.
    Sk UH; Kambhampati SP; Mishra MK; Lesniak WG; Zhang F; Kannan RM
    Biomacromolecules; 2013 Mar; 14(3):801-10. PubMed ID: 23373724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI; Powell W
    Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radioimmunoassay of 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Moffatt JG
    Methods Enzymol; 1982; 84():470-83. PubMed ID: 7098963
    [No Abstract]   [Full Text] [Related]  

  • 54. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
    Myers-Robfogel MW; Spataro AC
    Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolism of 1-beta-D-arabinofuranosylcytosine in leukemia L1210: nucleoside and nucleotide kinases in cell-free extracts.
    Schrecker AW
    Cancer Res; 1970 Mar; 30(3):632-41. PubMed ID: 5425288
    [No Abstract]   [Full Text] [Related]  

  • 57. Influence of tetrahydrouridine on the pharmacokinetics of intrathecally administered 1-beta-D-arabinofuranosylcytosine.
    Riccardi R; Chabner B; Glaubiger DL; Wood J; Poplack DG
    Cancer Res; 1982 May; 42(5):1736-9. PubMed ID: 6896013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transformation of 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine induced by hydrogen peroxide.
    Kikugawa K
    J Pharm Sci; 1975 Mar; 64(3):424-9. PubMed ID: 239190
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts.
    Jamieson GP; Finch LR; Snook M; Wiley JS
    Cancer Res; 1987 Jun; 47(12):3130-5. PubMed ID: 3472653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correspondence Re: L.E. Damon et al., Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res., 51: 4141-4145, 1991.
    Kreis W; Budman DR
    Cancer Res; 1992 Jul; 52(13):3818-20. PubMed ID: 1617654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.